Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03728166 · ClinicalTrials.gov registry record · NA

Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)

A NA study of Venous Thromboembolism, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
NA
Development phase
400
Enrollment target
1
Study location

NCT03728166: Recruiting NA study of Venous Thromboembolism, sponsored by Brigham and Women's Hospital.

NCT03728166 is a NA study of Venous Thromboembolism that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 400 participants, below the 6,287-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03728166, a NA study of Venous Thromboembolism, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target
1
Study location

Study Summary

Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care, including after hospital discharge. In the APEX Trial of hospitalized patients with acute medical illness, extended-duration post-discharge thromboprophylaxis with oral betrixaban reduced the frequency of asymptomatic proximal deep venous thrombosis (DVT), symptomatic proximal or distal DVT, symptomatic nonfatal pulmonary embolism (PE), or VTE-related death compared with short-duration enoxaparin. Obstacles to integration of these data in the hospitalized Medical Service patient population, including failure to identify at-risk patients, educational gaps in strategies for VTE prevention after discharge, and medication nonadherence, can be overcome with alert-based computerized decision support. This study is a single-center, 400-patient, randomized controlled trial of an EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase prescription of extended-duration post-discharge thromboprophylaxis and decrease symptomatic VTE in high-risk patients hospitalized with medical illness. Specific Aim #1: To determine the impact of electronic alert-based CDS (EPIC Best Practice Advisory \[BPA\]) on prescription of extended-duration post-discharge thromboprophylaxis in high-risk patients hospitalized with medical illness who are not being prescribed any prophylactic anticoagulation for VTE prevention after discharge. Specific Aim #2: To estimate the impact of electronic alert-based CDS (EPIC BPA) on the frequency of symptomatic VTE in high-risk patients hospitalized with medical illness who are not being prescribed any prophylactic anticoagulation for VTE prevention after discharge.

Primary Outcome

Investigators will review the order entry section of the Electronic Health Record (EPIC) to make this determination.

Conditions Studied

Interventions

  • BEHAVIORAL Electronic alert

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2019-02-01
Est. Completion 2026-06-30
Phase NA
Brigham and Women's Hospital

937 total trials

What NCT03728166 shows while recruiting

NCT03728166 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 6,287-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Electronic alert is the first listed.

NCT03728166 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03728166 about?

NCT03728166 is a clinical study titled "Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)". Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care, including after hospital discharge. In the APEX Trial of hospitalized patients with acute medical illness, extended-duration post-discharge thromboprophylaxis with oral betrixaban reduc...

What is the current status of trial NCT03728166?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2019-02-01. Estimated completion is 2026-06-30.

What conditions does trial NCT03728166 study?

This clinical trial studies the following conditions: Venous Thromboembolism.

What interventions are being tested in trial NCT03728166?

The interventions under investigation include: Electronic alert (BEHAVIORAL).

Who is sponsoring clinical trial NCT03728166?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03728166 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Thromboembolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03728166's enrollment target sits among peer trials

400 26th of 47 higher than 21 of 47 other Venous Thromboembolism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Venous Thromboembolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03728166, the US trial registry maintained by the National Library of Medicine. NCT03728166 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.